美国膀胱癌根治性膀胱切除术与三联疗法真实世界经济负担及医疗资源利用
基于2015年10月1日至2023年4月24日理赔数据,分析1323例接受根治性膀胱切除术(RC,839例)或三联疗法(TMT,484例)的膀胱癌患者。RC的90天中位费用为70671美元,5年升至211671美元;TMT的90天中位费用为34612美元,5年升至274462美元。RC费用主要由住院服务驱动,TMT以门诊费用为主。
要点
- RC队列90天中位费用70671美元,5年升至211671美元。
- TMT队列90天中位费用34612美元,5年升至274462美元。
- RC总就诊次中位数90天26次、5年163次;TMT分别为19次和186次。
核心结论
- RC费用主要驱动于住院服务,尤其是住院设施费用;TMT费用以门诊为主,驱动于药物管理和门诊放射设施。
- 这些治疗相关的可观费用和资源利用凸显了旨在改善患者结局的价值导向治疗方法的必要性。
研究设计与样本
- 利用2015年10月1日至2023年4月24日期间的理赔数据,评估患者特征、费用和医疗资源利用。
- 共纳入1323例患者,其中839例接受RC(中位年龄71岁;女性26.2%),484例接受TMT(中位年龄75岁;女性26.2%)。
- 随访时间从90天至5年,费用和资源利用按服务地点和具体费用驱动因素分解,并评估亚组以探索指南推荐方面。
主要发现
- RC队列中位每患者费用在90天随访时为70671美元(IQR 55878-106812),至索引后5年升至211671美元(IQR 138597-346389)。
- TMT队列总费用在90天时为34612美元(IQR 16705-64263),至5年增至274462美元(IQR 186337-421534)。
- 90天时,RC的中位总就诊次数(住院、门诊、急诊或其他)为26次(IQR 16-39),TMT为19次(IQR 12-33);至5年时,分别为163次(IQR 119-218)和186次(IQR 144-238)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To leverage contemporary real-world data to offer a comprehensive and longitudinal assessment of cost and healthcare resource utilization in patients with bladder cancer who underwent radical cystectomy (RC) or trimodal therapy (TMT). METHODS: Claims data between October 01, 2015, and April 24, 2023, were assessed to determine patient characteristics, costs, and healthcare resource utilization. Patients were followed from 90-days up to 5-years of follow-up. Costs and healthcare utilization were further broken down by place of service and specific cost drivers, and subgroups were assessed to explore aspects of treatment recommended guidelines. RESULTS: Of 1323 patients, 839 underwent RC (median age 71 years; 26.2% female), and 484 received trimodal therapy (median age 75; 26.2% female). Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index. For trimodal therapy, total costs were $34,612 [$16,705-$64,263] at 90-days and increased to $274,462 [$186,337-$421,534] by 5-years. At 90-days, median overall visits (inpatient, outpatient, emergency room, or other) were 26 [16-39] for RC and 19 [12-33] for trimodal therapy; overall visits were 163 [119-218] and 186 [144-238] by 5-years, respectively. CONCLUSION: This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs. For trimodal therapy, outpatient costs predominated, driven by drugs administered and outpatient radiology facilities. The considerable costs and utilization associated with these treatments underscore the need for value-based therapeutic approaches aimed at enhancing patient outcomes.
引用
- Williams SB, Yapici HO, Singhal PK, et al. Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States. Urology. 2025. PMID: 40122296. doi:10.1016/j.urology.2025.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。